Switch theme
Sign up to access all valuation multiples
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
2004
12
LTM Revenue n/a
LTM EBITDA n/a
$28.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akari Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Akari Therapeutics achieved revenue of n/a and an EBITDA of -$16.8M.
Akari Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akari Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$23.1M | -$16.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$17.4M | -$17.7M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Akari Therapeutics's stock price is $1.
Akari Therapeutics has current market cap of $29.5M, and EV of $28.2M.
See Akari Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.2M | $29.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Akari Therapeutics has market cap of $29.5M and EV of $28.2M.
Akari Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Akari Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Akari Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $28.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.7x | XXX | XXX | XXX |
| P/E | -2.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAkari Therapeutics's NTM/LTM revenue growth is n/a
Akari Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Akari Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Akari Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Akari Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akari Therapeutics acquired XXX companies to date.
Last acquisition by Akari Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Akari Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Akari Therapeutics founded? | Akari Therapeutics was founded in 2004. |
| Where is Akari Therapeutics headquartered? | Akari Therapeutics is headquartered in United States of America. |
| How many employees does Akari Therapeutics have? | As of today, Akari Therapeutics has 12 employees. |
| Who is the CEO of Akari Therapeutics? | Akari Therapeutics's CEO is Dr. Samir R. Patel, M.D.. |
| Is Akari Therapeutics publicy listed? | Yes, Akari Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Akari Therapeutics? | Akari Therapeutics trades under AKTX ticker. |
| When did Akari Therapeutics go public? | Akari Therapeutics went public in 2012. |
| Who are competitors of Akari Therapeutics? | Similar companies to Akari Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Akari Therapeutics? | Akari Therapeutics's current market cap is $29.5M |
| Is Akari Therapeutics profitable? | Yes, Akari Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
